Agios strengthens the case for mitapivat
A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.
After a big year, biotech flotations have much to do
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Agios gets $1.8bn and a new focus
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 – Forma gets an early edge over Agios in sickle cell disease
And both companies’ pyruvate kinase R activators could have Global Blood looking over its shoulder, though pain crises sow doubts.
Agios gets a pre-Ash boost
Mitapivat's pivotal win in a rare type of anaemia could bode well for its chances in thalassaemia and sickle cell disease.
